June 20, 2023
2 min watch
Save
VIDEO: Pirtobrutinib maintains positive responses for mantle cell lymphoma over 16 months
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Michael Choi, MD, discusses updated data on the results of pirtobrutinib treatments on mantle cell lymphoma, presented at ASCO Annual Meeting.
Choi, a hematologist/oncologist at UC San Diego Moores Cancer Center, highlighted the study, which showed maintained positive responses among patients with mantle cell lymphoma treated with pirtobrutinib (Jaypirca, Eli Lilly & Co.), while also maintaining a lack of any new emerging toxicity signals.
“It’s something we should continue to be vigilant about in tracking and reporting, but it seems that the [adverse event] profile that we’ve come to learn about pirtobrutinib is consistent through longer treatment,” Choi said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Choi reports receiving research funding for his institution from AbbVie, AstraZeneca, Beigene, Geron, MEI Pharma, Merck, Oncternal Therapeutics, Pharmacyclics, Protagonist Therapeutics and VelosBio, and noncompensated consulting for AbbVie.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.